Isoxazole compounds exhibit a wide spectrum of targets and broad biological activities.
Developing compounds with heterocycle rings has been one of the trends. The integration of …

RET receptor tyrosine kinase acts as a mutated oncogenic driver in several human
malignancies and it is over-expressed in other cancers. Small molecule compounds with …

A new class of pyrrolo [2′, 3′: 3, 4] cyclohepta [1, 2-d][1, 2] oxazoles was synthesized for
the treatment of hyperproliferative pathologies, including neoplasms. The new compounds …

A direct functionalization of unsubstituted isoxazole (1) was achieved by generation of 4‐
isoxazolyl anion species (3). An efficient 4‐iodination of isoxazole and halogen–metal …

REarranged during Transfection (RET) is a validated target for anticancer drug discovery
and two selective RET inhibitors were approved by US FDA in 2020. However, acquired …

Abstract Three series of pyrazolo [3, 4-d] pyrimidine derivatives were synthesized and
evaluated as RET kinase inhibitors. Compounds 23a and 23c were identified to show …

GNF-7, a multitargeted kinase inhibitor, served as a dual kinase inhibitor of ACK1 and GCK,
which provided a novel therapeutic strategy for overriding AML expressing NRAS mutation …

RET kinase gain-of-function mutations represent the main cause of the high aggressiveness
and invasiveness of medullary thyroid cancer (MTC). The selective inhibition of the RET …

Abstract A series of [1, 2] Oxazolo [5, 4-e] isoindoles has been synthesized through a
versatile and high yielding sequence. All the new structures showed in the 1 HNMR spectra …

The receptor tyrosine kinase rearranged during transfection (RET) plays pivotal roles in
several cancers, including thyroid carcinoma and non-small cell lung cancer (NSCLC) …